Georg-Peter Breitbach

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6347134/publications.pdf

Version: 2024-02-01

		1163117	940533	
16	662	8	16	
papers	citations	h-index	g-index	
16	16	16	835	
all docs	docs citations	times ranked	citing authors	

#	Article	IF	CITATIONS
1	A standardized simulation training program to type 1 loop electrosurgical excision of the transformation zone: a prospective observational study. Archives of Gynecology and Obstetrics, 2020, 301, 611-618.	1.7	4
2	Factors Influencing the Onset of Neoadjuvant Therapy in Breast Cancer Patients. Breast Care, 2020, 15, 182-187.	1.4	4
3	Factors influencing the time to surgery after neoadjuvant chemotherapy in breast cancer patients. Archives of Gynecology and Obstetrics, 2020, 301, 1055-1059.	1.7	9
4	Significant improvement of laparoscopic knotting time in medical students through manual training with potential cost savings in laparoscopy - an observational study. Journal of the Turkish German Gynecology Association, 2020, 21, 150-155.	0.6	7
5	Preoperative morphological diagnosis of axillary lymph nodes in a breast center consultation service: evaluation of fine-needle aspiration and core biopsy techniques. Archives of Gynecology and Obstetrics, 2019, 300, 1659-1670.	1.7	3
6	Therapy of isolated locoregional recurrent carcinoma of the breast. Archives of Gynecology and Obstetrics, 2019, 300, 365-376.	1.7	2
7	Oral etoposide for metastatic choriocarcinoma: a case report and review of guidelines. Archives of Gynecology and Obstetrics, 2019, 299, 1115-1119.	1.7	4
8	Sec62/Ki67 and p16/Ki67 dual-staining immunocytochemistry in vulvar cytology for the identification of vulvar intraepithelial neoplasia and vulvar cancer: a pilot study. Archives of Gynecology and Obstetrics, 2019, 299, 825-833.	1.7	10
9	Uterine Leiomyosarcoma. Oncology Research and Treatment, 2018, 41, 680-686.	1.2	35
10	Interest in Integrative Medicine Among Postmenopausal Hormone Receptor–Positive Breast Cancer Patients in the EvAluate-TM Study. Integrative Cancer Therapies, 2017, 16, 165-175.	2.0	22
11	Factors Influencing Decision-Making for or against Adjuvant and Neoadjuvant Chemotherapy in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study. Breast Care, 2016, 11, 315-322.	1.4	6
12	Phase II study of fulvestrant 250mg/month in patients with recurrent or metastatic endometrial cancer: A study of the Arbeitsgemeinschaft GynAkologische Onkologie. Gynecologic Oncology, 2013, 129, 495-499.	1.4	35
13	A Risk Model for Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer: An Evidence-Based Proposal for Patient Selection. Annals of Surgical Oncology, 2012, 19, 597-604.	1.5	109
14	Neoadjuvant chemotherapy with carboplatin and docetaxel in advanced ovarian cancer - a prospective multicenter phase II trial (PRIMOVAR). Oncology Reports, 2009, 22, 605-13.	2.6	34
15	Surgery in Recurrent Ovarian Cancer: The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR Trial. Annals of Surgical Oncology, 2006, 13, 1702-1710.	1.5	367
16	Dose-dense adjuvant chemotherapy for node-positive breast cancer in women 60 years and older: Feasibility and tolerability in a subset of patients in a randomized trial. Critical Reviews in Oncology/Hematology, 2006, 58, 166-175.	4.4	11